LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA) Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well ...

OKYO Pharma Ltd (NASDAQ: OKYO) announced Wednesday positive top-line data from its recently completed Phase 2 clinical trial of urcosimod, previously known as OK-101, for the treatment of NCP.

Basal and squamous cell skin cancer are the most common types of skin cancer. Learn more about basal and squamous cell skin cancer here.